People: Kips Bay Medical Inc (KIPS.PH)
KIPS.PH on Philadelphia Stock Exchange
1.44USD
15 Apr 2013
1.44USD
15 Apr 2013
Price Change (% chg)
$0.51 (+54.86%)
$0.51 (+54.86%)
Prev Close
$0.93
$0.93
Open
$1.44
$1.44
Day's High
$1.44
$1.44
Day's Low
$1.44
$1.44
Volume
400
400
Avg. Vol
27
27
52-wk High
$1.46
$1.46
52-wk Low
$0.87
$0.87
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Manuel Villafana |
72 | 2010 | Chairman of the Board, Chief Executive Officer |
Scott Kellen |
47 | 2012 | Chief Financial Officer, Chief Operating Officer, Vice President - Finance, Secretary |
Michael Reinhardt |
53 | 2011 | Vice President - Sales & Marketing |
Randall LaBounty |
49 | 2011 | Vice President - Regulatory and Clinical Affairs |
Robert Munzenrider |
68 | 2011 | Lead Independent Director |
Robert Sheehy |
55 | 2011 | Independent Director |
Arch Smith |
57 | 2011 | Independent Director |
Biographies
| Name | Description |
|---|---|
Manuel Villafana |
Mr. Manuel A. Villafana is Chairman of the Board, Chief Executive Officer of Kips Bay Medical Inc. Prior to founding the company and since 1999, Mr. Villafaña founded and served as Chairman of the Board and Chief Executive Officer of CABG Medical, Inc., formed to develop an artificial coronary graft for use in bypass surgery. From 1987 to 2004, Mr. Villafaña founded and served as Chairman of the Board and Chief Executive Officer of ATS Medical, Inc., which developed open-pivot mechanical heart valves. ATS Medical was subsequently acquired by Medtronic, Inc. From 1976 to 1982, Mr. Villafaña founded and served as President and Chairman of the Board of St. Jude Medical, Inc. From 1972 to 1976, Mr. Villafaña founded and served as President and Chairman of the Board of Cardiac Pacemakers, Inc., or CPI, a cardiac rhythm management company. CPI was ultimately acquired by Eli Lilly and Company, which spun out CPI as Guidant Corporation. Guidant was, in turn, purchased by Boston Scientific Corporation. Mr. Villafaña has received numerous awards and honors, including the "Living Legend of Medicine" award from the International Society of Cardio Thoracic Surgeons, the Ellis Island Medal of Honor, the Grand Prize Recipient—Mediterranean Institute of Cardiology, the Ernst & Young LLP National Master Entrepreneur of the Year, the Boys and Girls Club of America Hall of Fame, induction into the Minnesota Business Hall of Fame and, in 2010, induction into the Minnesota Science and Technology Hall of Fame. |
Scott Kellen |
Mr. Scott Kellen is Chief Financial Officer, Chief Operating Officer, Vice President - Finance, Secretary of Kips Bay Medical Inc. He has been appointed as Chief Operating Officer of the company on March 13, 2012. He joined the Company as Chief Financial Officer, Vice President of Finance, and Secretary on February 8, 2010. From 2007 to 2009, Mr. Kellen served as Director of Finance from 2007 to 2009 and Chief Financial Officer from February 1, 2009 to May 1, 2009 for Transoma Medical, Inc., including during the preparation of its proposed initial public offering, which was withdrawn in February 2008 due to deteriorated market conditions. From 2005 to 2007, Mr. Kellen served as the Corporate Controller for ev3 Inc. during the company's initial public offering and during additional follow-on offerings. From 2003 to 2005, Mr. Kellen served as Senior Audit Manager of Deloitte & Touche, LLP (now Deloitte LLP), providing auditing and consulting services to mid-size public companies after the passage of the Sarbanes-Oxley Act. Mr. Kellen has spent more than 15 years in the medical device industry, serving early stage and growth companies that produced Class II and III devices. Mr. Kellen began his career with Deloitte & Touche in 1987. |
Michael Reinhardt |
Mr. Michael E. Reinhardt is Vice President - Sales & Marketing of Kips Bay Medical Inc. He has nearly 25 years of experience in the medical device industry. From 2009 to 2010, Mr. Reinhart served as Vice President of Global Marketing for ATS Medical Inc. based in Minneapolis, MN which was focused on cardiac surgery and engaged in the development and commercialization of prosthetic heart valves, valvular repair devices and cryoablation products. ATS Medical was purchased in August, 2010 by Medtronic, Inc. From 2007 to 2009, Mr. Reinhardt served as an independent consultant providing strategic and operational planning and execution services to the medical device industry. Prior to 2007, Mr. Reinhardt had held several senior management level positions at companies including; St Jude Medical's Cardiac Surgery Division; C.R. Bard's Electrophysiology Division; Boston Scientific's Scimed Division; and Ethicon Endosurgery. He also has considerable International experience having worked in the European and Asian markets. He has a broad spectrum of experiences including working in the fields of general surgery, laparoscopic surgery, interventional cardiology, electrophysiology and cardiothoracic surgery. Mr. Reinhardt holds a B.A. in Marketing from Ohio University and a M.B.A. from Baruch College in New York, New York. |
Randall LaBounty |
Mr. Randall Keith LaBounty is Vice President - Regulatory and Clinical Affairs of Kips Bay Medical Inc., since May 2, 2011. Mr. LaBounty has over 20 years of experience in medical device research with 16 years of experience in cardiovascular medical devices. Prior to joining Kips Bay Medical, Mr. LaBounty served as Vice President of Clinical Research at Osprey Medical, Inc., a company focused on preventing contrast-induced chronic kidney diseases in patients, from 2010 to 2011 and Vice President of Clinical and Regulatory Affairs at Lumen Biomedical, Inc. from 2005 to 2010. He has also held director level positions at Atritech, Inc., ev3, Inc. and IntraTherapeutics, Inc. Mr. LaBounty has experience with Class II and Class III medical products. He has been involved in all phases of the medical device approval process including the development of clinical and regulatory strategies, clinical trial execution, obtaining FDA IDEs, PMAs and 510(k) submissions. Internationally, he has brought medical devices from initial clinical trials through to CE Mark approval. He has a Master of Science degree in Biostatistics and Bachelor of Science degree in Genetics and Cell Biology from the University of Minnesota. |
Robert Munzenrider |
Mr. Robert E. Munzenrider is Lead Independent Director of Kips Bay Medical Inc. He is the founder and co-founder of several e-commerce businesses. From 2000 to 2002, Mr. Munzenrider was President of Harmon AutoGlass, a subsidiary of Apogee Enterprises, Inc. In 1999, he served as Vice President and Chief Financial Officer of the Glass Services Segment of Apogee Enterprises. He also served as Executive Vice President and Chief Financial Officer of Eliance Corp., an e-commerce service provider, during part of 1999. From 1998 to 1999, Mr. Munzenrider served as Vice President and Chief Financial Officer of St. Jude Medical, Inc. Mr. Munzenrider has served on the board of directors for Viad Corp. since 2004 and Angeion Corp. since 2010. Mr. Munzenrider also served on the board of directors for Criticare Systems, Inc. from 2007 to 2008, the board of directors for CABG Medical, Inc. from 2004 to 2006, and the board of directors for ATS Medical, Inc. from 2003 to 2010. He is also a Trustee Emeritus on the University of Montana Foundation. |
Robert Sheehy |
Mr. Robert J. Sheehy is Independent Director of Kips Bay Medical Inc. He is an Operating Partner and member of the Strategic Advisory Board of Genstar Capital, a San Francisco based private equity firm that invests in middle-market companies. From 2007 to 2008, Mr. Sheehy served as Senior Vice President for UnitedHealth Group, Inc. From 2000 to 2007, Mr. Sheehy served as Chief Executive Officer of UnitedHealthcare, Inc., a division of UnitedHealth Group. From April 1998 to December 2000, Mr. Sheehy was President of UnitedHealthcare. Prior to April 1998, Mr. Sheehy served in various capacities with UnitedHealth Group. Mr. Sheehy currently serves on the board of directors for Univita Health, which he joined in March 2010, and Evolution1, Inc., which he joined in July 2011. Mr. Sheehy currently serves as the Chairman of the board of directors of West Side Community Health Services and as a member of the Board of Trustees of Breck School. |
Arch Smith |
Mr. Arch C. Smith is Independent Director of Kips Bay Medical Inc. He is currently a partner with Rothschild Capital Partners, focusing on investments in publicly traded medical device stocks. From April 2005 to May 2010, Mr. Smith was a Venture Partner at Sight Line Partners, a venture capital firm focused on investments in later stage private medical device companies. From 1984 to 2003, Mr. Smith worked for Piper Jaffray, a Minneapolis-based investment bank. Mr. Smith contributed in roles of increasing responsibility and most recently as a senior healthcare analyst and Managing Director for equity research, specializing in medical technology companies. Mr. Smith initially covered capitalization stocks in the cardiovascular device arena, but later shifted the focus of his practice to small capitalization medical technology companies. Mr. Smith served on the board of directors for CABG Medical, Inc. from 2004 to 2006. During his employment with Sight Line Partners, Mr. Smith served on the board of directors of Centerre Healthcare, PHT Corporation and InSound Medical. Mr. Smith serves on the board of the Minneapolis Heart Institute Foundation. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Manuel Villafana |
336,916 |
Scott Kellen |
330,953 |
Michael Reinhardt |
-- |
Randall LaBounty |
400,497 |
Robert Munzenrider |
-- |
Robert Sheehy |
-- |
Arch Smith |
-- |
As Of 30 Dec 2011
Options Compensation
| Name | Options | Value |
|---|---|---|
Manuel Villafana |
0 | 0 |
Scott Kellen |
0 | 0 |
Michael Reinhardt |
0 | 0 |
Randall LaBounty |
0 | 0 |
Robert Munzenrider |
0 | 0 |
Robert Sheehy |
0 | 0 |
Arch Smith |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
SMITH ARCH C |
15,000 | $0.00 |
MUNZENRIDER ROBERT EMMETT |
15,000 | $0.00 |
SHEEHY ROBERT J |
15,000 | $0.00 |
KIPS BAY INVESTMENTS L L C |
4,900 | $1.00 |
KIPS BAY INVESTMENTS L L C |
200 | $0.99 |
KIPS BAY INVESTMENTS L L C |
22,500 | $1.00 |
KIPS BAY INVESTMENTS L L C |
690 | $1.00 |
KIPS BAY INVESTMENTS L L C |
6,864 | $1.00 |
KIPS BAY INVESTMENTS L L C |
8,950 | $1.00 |
VILLAFANA MANUEL A |
200,000 | $0.00 |
SHEEHY ROBERT J |
15,000 | $0.00 |
MUNZENRIDER ROBERT EMMETT |
15,000 | $0.00 |
SMITH ARCH C |
15,000 | $0.00 |
VILLAFANA MANUEL A |
29,150 | $1.69 |
KIPS BAY INVESTMENTS L L C |
2,400 | $1.35 |
KIPS BAY INVESTMENTS L L C |
500 | $1.35 |
KIPS BAY INVESTMENTS L L C |
500 | $1.35 |
KIPS BAY INVESTMENTS L L C |
2,400 | $1.35 |
VILLAFANA MANUEL A |
15,000 | $3.90 |
VILLAFANA MANUEL A |
7,703 | $3.83 |
VILLAFANA MANUEL A |
5,894 | $3.99 |
VILLAFANA MANUEL A |
7,703 | $4.10 |
VILLAFANA MANUEL A |
6,703 | $3.43 |
VILLAFANA MANUEL A |
4,622 | $3.02 |
VILLAFANA MANUEL A |
4,622 | $3.00 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
